For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Editas Medicine Inc (NASDAQ: EDIT) closed at $5.60 in the last session, up 2.00% from day before closing price of $5.49. In other words, the price has increased by $2.00 from its previous closing price. On the day, 1.75 million shares were traded. EDIT stock price reached its highest trading level at $5.79 during the session, while it also had its lowest trading level at $5.3899.
Ratios:
We take a closer look at EDIT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.39 and its Current Ratio is at 5.39. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.07.
On October 18, 2023, JP Morgan Upgraded its rating to Neutral which previously was Underweight but kept the price unchanged to $8.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 05 ’24 when O’Neill Gilmore Neil sold 77,824 shares for $9.42 per share. The transaction valued at 732,884 led to the insider holds 327,470 shares of the business.
Mei Baisong sold 20,327 shares of EDIT for $191,425 on Mar 04 ’24. The SVP, CHIEF MEDICAL OFFICER now owns 141,543 shares after completing the transaction at $9.42 per share. On Dec 05 ’23, another insider, Eaton Bruce, who serves as the EVP, CBO AND CTO of the company, sold 103 shares for $10.90 each. As a result, the insider received 1,122 and left with 74,791 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EDIT now has a Market Capitalization of 460514336 and an Enterprise Value of 171582560. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.89 while its Price-to-Book (P/B) ratio in mrq is 1.31. Its current Enterprise Value per Revenue stands at 2.196 whereas that against EBITDA is -1.052.
Stock Price History:
The Beta on a monthly basis for EDIT is 2.06, which has changed by -0.27272725 over the last 52 weeks, in comparison to a change of 0.23061275 over the same period for the S&P500. Over the past 52 weeks, EDIT has reached a high of $11.91, while it has fallen to a 52-week low of $5.28. The 50-Day Moving Average of the stock is -27.81%, while the 200-Day Moving Average is calculated to be -33.33%.
Shares Statistics:
According to the various share statistics, EDIT traded on average about 1.92M shares per day over the past 3-months and 1794880 shares per day over the past 10 days. A total of 81.77M shares are outstanding, with a floating share count of 81.24M. Insiders hold about 1.21% of the company’s shares, while institutions hold 77.60% stake in the company. Shares short for EDIT as of 1711584000 were 16363151 with a Short Ratio of 8.52, compared to 1709164800 on 13517811. Therefore, it implies a Short% of Shares Outstanding of 16363151 and a Short% of Float of 28.100002000000003.
Earnings Estimates
The current rating of Editas Medicine Inc (EDIT) is the result of assessments by 14 analysts actively engaged in evaluating its market dynamics.On average, analysts expect EPS of $-0.67 for the current quarter, with a high estimate of $-0.44 and a low estimate of $-1.09, while EPS last year was $-0.71. The consensus estimate for the next quarter is $-0.67, with high estimates of $-0.46 and low estimates of $-1.11.
Analysts are recommending an EPS of between $-1.84 and $-3.83 for the fiscal current year, implying an average EPS of $-2.66. EPS for the following year is $-2.74, with 15 analysts recommending between $-1.72 and $-4.51.
